Public health benefits of shifting from inpatient to outpatient 2 TB care in Eastern Europe: optimising TB investments in 3 Belarus, the Republic of Moldova, and Romania

2


Introduction 45
In most Eastern European countries, the TB care model is based on legacy systems of inpatient care with 46 injectable DR TB treatment. Historical models used long-term quarantine and allowed TB patients to 47 68 In most Eastern European countries, the TB care model is based on legacy systems of inpatient care with 69 injectable DR TB treatment. Historical models used long-term quarantine and allowed TB patients to 70 recover over time, as they were developed at a time when effective DR TB drugs were not available and

71
MDR TB did not exist (1). Particularly once effective DR TB drugs became available, the emergence and 72 persistence of DR TB is a direct consequence of failings in the health care system (1). However, 73 regardless of the availability of effective DR TB drug regimens and updated global health guidance, lengthy 74 inpatient care models persist in most Eastern European countries and barriers to adopting outpatient DR TB 75 treatment models still exist. These may involve health financing mechanisms that reimburse based on 76 hospital bed occupancy rates for DR TB care or financing frameworks based on a restrictive line item 77 budget making purchaser-provider split impossible. To overcome these types of barriers, solutions for 78 health financing reform should consider results-based reimbursement and financing frameworks should 79 allow for a more flexible global budget (1).

81
Avoiding hospital admissions, particularly to facilities with inadequate mechanisms for infection control,

82
has been a key factor in reducing the risk of nosocomial transmission including the spread of TB and DR 83 TB (1). Moreover, with the onset of the COVID-19 pandemic in early 2020, there has been an accelerated 84 move to outpatient TB care to avoid the risk of SARS-CoV-2 infection for services sought in hospital. This

85
shift is anticipated to continue in line with recommendations from the three country studies considered here.

86
While some provision for inpatient TB care will likely remain to deliver specialised care for those with 87 particularly complex cases, this shift to outpatient care is anticipated to continue.

89
While the overall burden of TB in Eastern Europe has declined in the last two decades, the incidence of 90 drug-resistant TB has increased. In Belarus, the Republic of Moldova, and Romania, TB incidence, active 91 TB prevalence, and TB-related deaths declined between 2000 and 2015, while the relative share of 92 multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB increased or continued over this . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 17, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022 93 period or at least did not decrease in these countries (key country information listed in Table 1). It is worth 94 keeping in mind that the capacity to detect DR TB has significantly improved over the past decade (7). This 95 has mainly been due to improved access to diagnostic technologies and rollout of rapid molecular 96 diagnostics in high-burden countries. In this study we focus on three case study countries in Eastern Europe where TB outpatient care programs 104 have been defined. We compare optimised outcomes based on the savings gained from shifting to less . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 17, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 17, 2022. ; https://doi.org/10.1101/2022.08.16.22278850 doi: medRxiv preprint Republic of Moldova, and Romania. All studies were conducted in collaboration with local stakeholders.

131
An analysis was conducted in 20162017 for Belarus with a full description of the methodology provided 132 in (8). Analyses were conducted in 20172018 for the Republic of Moldova as described in (10) and

133
Romania as described in (13) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 17, 2022. hospital-based treatment, then the model algorithm will relocate resources accordingly.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 17, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022 For this modelling analysis it was assumed that any savings from prioritising more cost-effective ambulatory treatment modalities should be prioritised. This will lead to cost savings, with the 207 recommendation to reinvesting these savings to increase ambulatory treatment coverage. This also includes 208 the earlier diagnosis of additional TB cases, which in turn will allow more people to receive treatment. The

209
number of cumulative active TB cases and TB-related deaths that could be averted by 2035 were estimated.

210
The reduction in the prevalence of active TB that could be achieved over this period was also projected.

211
This analysis draws together common results and conclusions from TB budget impact studies for Belarus,  (Fig. 1). At the time of this . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 17, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 17, 2022.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 17, 2022. Belarus and 21% in Romania) over this period (Fig. 3 with corresponding estimates reported in Supporting . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 17, 2022. ; https://doi.org/10.1101/2022.08.16.22278850 doi: medRxiv preprint Information Tables S6S8). Focusing on maximising TB outcomes, not considering potential benefits for 296 other areas of health, modelling shows these savings should be optimally reinvested in TB prevention, 297 diagnosis, and ambulatory treatment interventions to increase treatment coverage. In each country,

298
increased investment in active case finding (particularly in high incidence areas and to target high-risk 299 groups) and prevention was projected to lead to rapid decreases in the prevalence of active TB prevalence 300 and TB-related mortality, but the high burden of latent TB means that new active TB infections are projected 301 to decline more slowly.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 17, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022 that was in conflict with the recommendation, and which indicated that treatment in a hospital-focused 320 model of care leads to a more favourable treatment outcome" (5). Here we demonstrate that transitioning 321 from hospital-to ambulatory-based DR TB treatment could yield savings of 31%, 5%, and 19% in Belarus,

322
Moldova, and Romania, respectively, while achieving at least comparable projected treatment outcomes 323 (Figs. 2 and 3). It is recommended that these savings be optimally reinvested in TB prevention, diagnosis,

324
and outpatient treatment to achieve increased treatment coverage and further health gains.

342
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) country studies and disease areas will also be included.

361
The COVID-19 pandemic has resulted in a shift to outpatient care to avoid the risk of SARS-CoV-2 362 infection. This was achieved through technical advances including telehealth, video supported treatment,

363
and other lower contact service delivery approaches. Many of these innovations were in place before the 364 pandemic, but the pandemic prompted the transition to utilise these modalities making it more convenient 365 and decreasing the burden for both patients and providers in ambulatory settings. It is anticipated that many 366 of these care options will continue, even once the need for the COVID response lessens. Given the potential 367 gains from furthering shift towards outpatient care, as estimated here, it would be advantageous for TB 368 programme planners to continue incorporating this shift in service delivery into ongoing TB response plans.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 17, 2022. ; https://doi.org/10.1101/2022.08.16.22278850 doi: medRxiv preprint 369 370 Following global guidelines to transition away from hospital-based to outpatient DR TB care (5) there are 371 other benefits beyond cost savings, which were not captured in this analysis. Other benefits include reduced 372 nosocomial transmission-related health systems costs, cost (direct and indirect) to the patient, as well as 373 reduction in infection risk, and stigma surrounding access to longer-term hospital care. It may also be worth 374 exploring the cost-effectiveness of integrating DR TB care services with other health programs, particularly 375 those delivered more readily in ambulatory care settings, such as mental health services and alcohol 376 cessation support. One such example is for people coinfected with TB and HIV; co-treatment could be 377 decentralised through ambulatory care and therefore be more patient-centered, could result in healthcare 378 cost savings, reduced loss in income through avoided hospital stays, and other benefits (21).

380
An international systematic review of the evidence supports the assumption that ambulatory care could 381 achieve current coverage levels in target populations (22). A meta-analysis of 540 articles reported no 382 statistical difference for treatment outcome rates (success, death, default, and failure), between ambulatory 383 and hospital-focused delivery of TB care. The review found that standard ambulatory care can be as 384 effective as hospital-focused care (22). There is also evidence to suggest that ambulatory care that is 385 enhanced by specific incentives might be more effective than standard ambulatory care. A Cochrane review 386 suggested that ambulatory care coupled with cash incentives for patients may be more effective than non-387 incentivised ambulatory care, particularly among high-risk groups (23). A WHO review of evidence also 388 suggests improvements in treatment adherence through food and financial support as well as TB care 389 enhanced through a mix of interventions (24). Considerations around a complete shift from hospital-focused 390 to ambulatory care are that comorbidities, including alcohol use disorder, and coinfection with HIV (non-391 homogeneous), are also common in this region. In future, more complex cases will likely still need at least 392 some hospitalised care.

393
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 17, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022